The current classification of urothelial neoplasms

Modern Pathology

Volumn 22, Issue , 2009, Pages S60-S69

  Grignon, David J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Classification; Grading; Prognosis; Treatment; Urothelial neoplasms

Indexed keywords

BCG VACCINE; CYTOKERATIN 20; PROTEIN P53;

BLADDER CANCER; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GRADING; CANCER IMMUNOTHERAPY; CARCINOMA IN SITU; CLINICAL PRACTICE; DISEASE COURSE; DYSPLASIA; HISTOLOGY; HUMAN; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; PAPILLARY CARCINOMA; PATHOLOGIST; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT INDICATION; UROGENITAL TRACT TUMOR; UROTHELIAL PAPILLOMA; WORLD HEALTH ORGANIZATION;

CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; HUMANS; PRACTICE GUIDELINES AS TOPIC; URINARY BLADDER NEOPLASMS;

EID: 67149102154     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.235     Document Type: Article

References (55)

1. Mostofi FK, Sobin LH. Histologic Typing of Urinary Bladder Tumors. World Health Organization: Geneva, 1973.
2. Murphy WM, Beckwith JB, Farrow GM. Atlas of Tumor Pathology: Tumors of the Kidney, Bladder, and related Urinary Structures. Armed Forces Institute of Pathology 3rd series fascicle American Registry of Pathology: Washington, DC, 1994.
3. Jordan AM, Weingarten J, Murphy WM. Transitional neoplasms of the urinary bladder, can biological potential be predicted from histological grading. Cancer 1987;60:2766-2774.
4. Witjes JA, Moonen PMJ, van der Heijden AG. Review pathology in a diagnostic bladder cancer trial: effect on patient risk category. Urology 2006;67:751-755.
5. Kiemeney LALM, Witjes JA, Verbeek ALM, et al. The clinical epidemiology of superficial bladder cancer. Br J Cancer 1993;67:806-812.
6. Bostwick DG, Mikuz G. Urothelial papillary (exophytic) neoplasms. Virch Arch 2002;441:109-116.
7. Epstein JI, Amin MB, Reuter VR, et al. The World Health Organization/International Society of Urologic Pathology consensus classification of urothelial (transitional) neoplasms of the urinary bladder. Am J Surg Pathol 1998;22:1435-1448.
8. Malmström PU, Busch C, Norlen BJ. Recurrence, progression and survival in bladder cancer: a retrospective analysis of 232 patients with greater than or equal to 5-year follow-up. Scand J Urol Nephrol 1987;21:185-195.
9. Mostofi FK, Jr. Davis CJ, Sesterhenn IA. Histological Typing of Urinary Bladder Tumors: International Histological Classification of Tumors. World Health Organization: Geneva, 1999.
10. Cheng L, Bostwick DG. World Health Organization and International Society of Urologic Pathology Classification and a two-number grading system of bladder tumors. Cancer 2000;88:1513-1516.
11. Oyasu R. World Health Organization and International Society of Urological Pathology Classification and twonumber grading system of bladder tumors. Cancer 2000;88:1509-1512.
12. Lopez-Beltran A, Montironi R. Non-invasive urothelial neoplasms: according to the most recent WHO classification. Eur Urol 2004;46:170-176.
13. Eble JN, Epstein JI, Sauter G, et al. World Health Organization Histologic and Genetic Typing of Tumors of the Kidney, Urinary Bladder, Prostate Gland and Testis. IARC Press: Lyon, 2004.
14. Murphy WM, Grignon DJ, Perlman E. Atlas of Tumor Pathology: Tumors of the Kidney, Bladder, and related Urinary Structures. Armed Forces Institute of Pathology 4th series fascicle American Registry of Pathology: Washington, DC, 2004.
15. Reuter VE. The pathology of bladder cancer. Urology 2006;67(Suppl 3A):11-18.
16. Samaratunga H, Makarov DV, Epstein JI. Comparison of WHO/ISUP and WHO classification of noninvasive papillary urothelial neoplasms for risk of progression. Urology 2002;60:315-319.
17. Yin H, Leong AS-Y. Histologic grading of noninvasive papillary urothelial tumors: validation of the 1998 WHO/ISUP system by immunophenotyping and follow up. Am J Clin Pathol 2004;121:679-687.
18. Herr HW, Donat SM, Reuter VE. Management of low grade papillary bladder tumors. J Urol 2007;178:1201-1205.
19. Burger M, van der Aa MNM, van Oers JMM, et al. Prediction of progression on non-muscle invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur Urol 2008;54:835-844.
20. Herr HW. Low risk bladder tumors—less is more. J Urol 2008;179:13-14.
21. Nieder AM, Soloway MS. Eliminate the term ‘superficial’ bladder cancer. J Urol 2006;175:417-418.
22. Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of non muscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007;178:2314-2330.
23. Amin MB, Srigley JR, Grignon DJ, et al. Urinary Bladder, ureter, and renal pelvis: protocol applies to all carcinomas of the urinary bladder, ureter and renal pelvis. Arch Pathol Lab Med 2003;127: 1263-1279 (Protocol revision date, January 2005; CAP Web page:http://www.cap.org/apps/docs/cancer_protocols/2005/urbladder05_pw.pdf).
24. Cheng L, Cheville JC, Neumann RM, et al. Flat intraepithelial lesions of the urinary bladder. Cancer 2000;88:625-631.
25. Murphy WM, Busch C, Algaba F. Intraepithelial lesions of urinary bladder: morphologic considerations. Scand J Urol Nephrol Suppl 2000;205:67-81.
26. Obermann EC, Junker K, Stoehr R, et al. Frequent genetic alterations in flat urothelial hyperplasia and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analysis. J Pathol 2003;199: 50-57.
27. Cheng L, Cheville JC, Neumann RM, et al. Natural history of urothelial dysplasia of the bladder. Am J Surg Pathol 1999;23:443-447.
28. Farrow G. Pathology of carcinoma in situ of the urinary bladder and related lesions. J Cell Biochem 1992;161:39-43.
29. Orozco R, Martin A, Murphy W. Carcinoma in situ of the urinary bladder: clues to host involvement in human carcinogenesis. Cancer 1994;74:115-122.
30. Melamed M, Voutsa N, Grabstald H. Natural history and clinical behavior of in situ carcinoma of the human urinary bladder. Cancer 1964;17:1533-1545.
31. Cheng L, Cheville JC, Neumann RM, et al. Survival of patients with carcinoma in situ of the urinary bladder. Cancer 1999;85:2469-2474.
32. Gofrit ON, Pode D, Pizov G, et al. The natural history of bladder carcinoma in situ after an initial response to bacillus Calmette-Guerin immunotherapy. Urol Oncol 2008; e-pub ahead of print.
33. Sylvester RJ, van der Meijden A, Witjes JA, et al. Highgrade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 2005;66(6 Suppl 1):90-107.
34. McKenney JK, Amin MB. The role of immunohistochemistry in the diagnosis of urinary bladder neoplasms. Semin Diagn Pathol 2005;22:69-87.
35. Yin H, He Q, Li T, et al. Cytokeratin 20 and Ki-67 to distinguish carcinoma in situ from flat non-neoplastic urothelium. Appl Immunohistochem Mol Morphol 2006;14:260-265.
36. Yin M, Bastacky S, Parwani AV, et al. p16(ink4) immunoreactivity is a reliable marker for urothelial carcinoma in situ. Hum Pathol 2008;39:527-535.
37. Cheng L, Bostwick DG. Overdiagnosis of bladder carcinoma. Anal Quant Cytol Histol 2008;30:261-264.
38. Jones EC. Urinary bladder. Mimics of neoplasia and new pathologic entities. Urol Clin North Am 1999;26:509-534.
39. Taylor DC, Bhagavan BS, Larsen MP, et al. Papillary urothelial hyperplasia: a precursor to papillary neoplasm. Am J Surg Pathol 1996;20:1481-1488.
40. Eble JN, Young RH. Benign and low grade papillary lesions of the urinary bladder: a review of the papilloma-papillary carcinoma controversy and a report of 5 typical papillomas. Semin Diag Pathol 1987;6:351-371.
41. Mostofi FK. Pathological aspects and spread of carcinoma of the bladder. JAMA 1968;206:1764-1771.
42. Cheng L, Darson M, Cheville JC, et al. Urothelial papilloma of the bladder: clinical and biologic implications. Cancer 1999;86:2098-2101.
43. McKenney JK, Amin MB, Young RH. Urothelial (transitional cell) papilloma of the urinary bladder: a clinicopathologic study of 26 cases. Mod Pathol 2003;16:623-629.
44. Sung M-T, MacLennan GT, Lopez-Beltran A, et al. Natural history of urothelial inverted papilloma. Cancer 2006;107:2622-2627.
45. Cheng CW, Chan LW, Chan CK, et al. Is surveillance necessary for inverted papilloma in the urinary bladder and urethra? ANZ J Surg 2005;75:213-217.
46. Jones TD, Zhang S, Lopez-Beltran A, et al. Urothelial carcinoma with an inverted growth pattern can be distinguished from inverted papilloma by fluorescence in situ hybridization immunohistochemistry and morphologic analysis. Am J Surg Pathol 2007;31:1861-1867.
47. Amin MB, Gomez JA, Young RH. Urothelial transitional cell carcinoma with endophytic growth patterns: a discussion of patterns of invasion and problems associated with assessment of invasion in 18 cases. Am J Surg Pathol 1997;21:1057-1068.
48. Broussard JN, Tan PH, Epstein JI. Atypia in inverted urothelial papillomas: pathology and prognostic significance. Hum Pathol 2004;35:1499-1504.
49. Cheng L, Neumann RL, Bostwick DG. Papillary urothelial neoplasms of low malignant potential: clinical and biological implications. Cancer 1999;86:2102-2108.
50. Holmang S, Andius P, Hedelin H, et al. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol 2001;165:1124-1128.
51. Oosterhuis JW, Schapers RF, Janssen-Heijnen ML, et al. Histological grading of papillary urothelial carcinoma of the bladder: prognostic value of the 1998 WHO/ISUP classification system and comparison with conventional grading systems. J Clin Pathol 2002;55:900-905.
52. Campbell PA, Conrad RJ, Campbell CM, et al. Papillary urothelial neoplasm of low malignant potential: reliability of diagnosis and outcome. BJU Int 2004;93:1228-1291.
53. Cheng L, Neumann RM, Nehra A, et al. Cancer heterogeneity and its biological implications in the grading of urothelial carcinoma. Cancer 2000;88:1663-1670.
54. Cina SJ, Lancaster-Weiss KJ, Lecksell K, et al. Correlation of Ki67 and p53 with the new World Health Organization/International Society of Urological Pathology classification system for urothelial neoplasms. Arch Pathol Lab Med 2001;125:646-651.
55. Pich A, Chiusa L, Formiconi A, et al. Biological differences between noninvasive papillary urothelial neoplasms of low malignant potential and low-grade (grade 1) papillary carcinoma of the bladder. Am J Surg Pathol 2001;25:1528-1533.